Monkeypox Is A Different Drug Development Ballgame From COVID-19

Company Shifts Focus To Randomized Trials For EUA

SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.

SIGA's smallpox drug, Tpoxx, is moving through multiple clinical trials for monkeypox worldwide • Source: Shutterstock

Despite early fears of a large-scale epidemic, the monkeypox outbreak in the US has already begun to plateau. But despite the public health emergency that the Department of Health and Human Services declared on 4 August, the development of drugs and vaccines to address monkeypox differs markedly from development of countermeasures for the COVID-19 pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D